Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection

Journal of Virology

Volumn 76, Issue 24, 2002, Pages 12735-12746

  Himoudi, Nourredine ^a   Abraham, Jean Daniel ^b   Fournillier, Anne ^a   Lone, Yu Chun ^c   Joubert, Aurélie ^a   De Beeck, Anne Op ^d   Freida, Delphine ^a   Lemonnier, François ^c   Kieny, Marie Paule ^b   Inchauspé, Geneviève ^a  

^a UNIVERSITÉ DE LYON   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; HEPATITIS C VACCINE; PHENYLALANYLLEUCYLPROLYLSERYLASPARTYLTYROSYLPHENYLALANYLPROLYLSERYLVALINE; SYNTHETIC PEPTIDE; THREONYLPROLYLPROLYLALANYLTHREONYLARGINYLPROLYLPROLYLASPARAGYLALANYLPROLYLI SOLEUCYLLEUCINE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION; VIRUS NUCLEOCAPSID; VIRUS RECOMBINANT;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HLA-A2 ANTIGEN; IMMUNIZATION; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL VACCINES;

EID: 0036891882     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.24.12735-12746.2002     Document Type: Article

References (51)

1. Altfeld, M., E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, P. E. Sax, S. Boswell, J. O. Kahn, C. Brander, P. J. Goulder, J. A. Levy, J. I. Mullins, and B. D. Walker. 2001. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193:169-180.
2. Battegay, M., J. Fikes, A. M. Di Bisceglie, P. A. Wentworth, A. Sette, F. Celis, W. M. Ching, A. Grakoui, C. M. Rice, and K. Kurokohchi. 1995. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 69:2462-2470.
3. Bertoletti, A., and M. K. Maini. 2000. Protection or damage: A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr. Opin. Immunol. 12:403-408.
4. Boyer, J. D., B. Wang, K. E. Ugen, M. Agadjanyan, A. Javadian, P. Frost, K. Dang, R. A. Carrano, R. Ciccarelli, L. Coney, W. V. Williams, and D. B. Weiner. 1996. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J. Med. Primatol. 25:242-250.
5. Brinster, C., S. Muguet, Y. C. Lone, D. Boucreux, N. Renard, A. Fournillier, F. Lemonnier, and G. Inchauspe. 2001. Different hepatitis C virus nonstructural protein 3 (NS3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34:1206-1217.
6. Brinster, C., M. Chen, D. Boucreux, G. Paranhos-Baccala, P. Liljestrom, F. Lemmonier, and G. Inchauspe. 2002. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 83:369-381.
7. Calarota, S., G. Bratt, S. Nordlund, J. Hinkula, A. C. Leandersson, E. Sandstrom, and B. Wahren. 1998. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 2:1320-1325.
8. Cerny, A., J. G. McHutchison, C. Pasquinelli, M. E. Brown, M. A. Brothers, B. Grabscheid, P. Fowler, M. Houghton, and F. V. Chisari. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Investig. 95:521-530.
9. Chartier, C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:805-4810.
10. Chen, W., S. Khilko, J. Fecondo, D. H. Margulies, and J. McCluskey. 1994. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J. Exp. Med. 180:1471-1483.
11. Cooper, S., A. L. Erickson, E. J. Adams, J. Kansopon, A. J. Weiner, D. Y. Chien, M. Houghton, P. Parham, and C. M. Walker. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449.
12. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71:6011-6019.
13. Erickson, A. L., Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, J. Sidney, D. McKinney, A. Sette, A. L. Hughes, and C. M. Walker. 2001. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15:883-895.
14. Fournillier, A., C. Wychowski, D. Boucreux, T. F. Baumert, J. C. Meunier, D. Jacobs, S. Muguet, E. Depla, and G. Inchauspe. 2001. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J. Virol. 75:2088-2097.
15. Grabowska, A. M., F. Lechner, P. Klenerman, P. J. Tighe, S. Ryder, J. K. Ball, B. J. Thomson, W. L. Irving, and R. A. Robins. 2001. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur. J. Immunol. 31:2388-2394.
16. + T lymphocytes after infection with hepatitis C virus. J. Virol. 75:5550-5558.
17. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA 96:5692-5697.
18. + T-cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167:7180-7191.
19. Kato, N., M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, and K. Shimotohno. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. USA 87:9524-9528.
20. Koziel, M. J., D. Dudley, N. Afdhal, A. Grakoui, C. M. Rice, Q. L. Choo, M. Houghton, and D. B. Walker. 1995. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus: Identification of multiple epitopes and characterization of patterns of cytokine release. J. Clin. Investig. 96:2311-2321.
21. Lechner, F., D. Wong, P. Dunbar, R. Chapman, R. Chung, P. Dohrenwend, G. Robbins, R. Philips, P. Klenerman, and B. Walker. 2000. Analysis of a successful immune response in persons infected with hepatitis C virus. Exp. Med. 191:1499-1512.
22. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur. J. Immunol. 30:2479-2487.
23. Lehner, P. J., and P. Cresswell. 1996. Processing and delivery of peptides presented by MHC class I molecules. Curt. Opin. Immunol. 8:59-67.
24. Leitner, W. W., M. C. Seguin W. R. Ballou, J. P. Seitz, A. M. Schultz, M. J. Sheehy, and J. A. Lyon. 1997. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 15:6112-6119.
25. Liu, Q., C. Tackney, R. A. Bhat, A. M. Prince, and P. Zhang. 1997. Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J. Virol. 71:657-662.
26. Lone, Y.-C., I. Motta, E. Mottez, Y. Guilloux, A. Lim, F. Demay, J.-P. Levraud, P. Kourilsky, and J.-P. Abastado. 1998. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. J. Immunother. 21:283-294.
27. Lusky, M., M. Christ, K. Rittner, A. Dieterle, D. Dreyer, B. Mourot, H. Schultz, F. Stoeckel, A. Pavirani, and M. Mehtali. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72:2022-2032.
28. Major, M. E., L. Vitvitski, J. Dubuisson, A. Fournillier, G. De Martynoff, C. Trepo, and G. Inchauspe. 1997. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J. Virol. 71:7101-7109.
29. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
30. Niedermann, G., E. Geier, M. Lucchiari-Hartz, N. Hitziger, A. Ramsperger, and K. Eichmann. 1999. The specificity of proteasomes: Impact on MHC class I processing and presentation of antigens. Immunol. Rev. 172:24-29.
31. b β2m double knockout mice. J. Exp. Med. 185:2043-2051.
32. Peet, N. M., J. A. McKeating, B. Ramos, T. Klonisch, J. B. De Souza, P. J. Delves, and T. Lund. 1997. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120. Clin. Exp. Immunol. 109:226-232.
33. + T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur. J. Immunol. 31:894-906.
34. Ramsay, A. J., J. Ruby, and I. A. Ramshaw. 1993. A case for cytokines as effector molecules in the resolution of virus infection. Immunol. Today 14:155-157.
35. Rehermann, B., and F. V. Chisari. 2000. Cell mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242:299-325.
36. Rehermann, B., K. M. Chang, J. G. McHutchison, R. Kokka, M. Houghton, and F. V. Chisari. 1996. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Investig. 98:1432-1440.
37. Reich, N. C., P. Sarnow, E. Duprey, and A. J. Levine. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 30:480-484.
38. Rosen, H. R., J. G. McHutchison, A. J. Conrad, J. J. Lentz, G. Marousek, S. L. Rose, A. Zaman, K. Taylor, and S. Chou. 2002. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis. Am. J. Gastroenterol. 97:714-720.
39. Santra, S., J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, C. I. Lord, R. Pal, G. Franchini, and N. L. Letvin. 2002. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J. Immunol. 168:1847-1853.
40. Seth, A., I. Ourmanov, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, L. Wyatt, M. Carroll, B. Moss, D. Venzon, N. L. Letvin, and V. M. Hirsch. 2000. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74:2502-2509.
41. Shimbara, N., K. Ogawa, Y. Hidaka, H. Nakajima, N. Yamasaki, S. Niwa, N. Tanahashi, and K. Tanaka. 1998. Contribution of proline residue for efficient production of MHC class I ligands by proteasomes. J. Biol. Chem. 273:23062-23071.
42. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 17:331-335.
43. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 30:605-609.
44. Takaki, A., M. Wiese, G. Maertens, E. Depla, U. Eifert, A. Liebetrau, J. L. Miller, M. P. Manns, and B. Rehermann. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6:578-582.
45. Thimme, R., D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 19:1395-1406.
46. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
47. Vertuani, S., M. Bazzaro, G. Gualandi, F. Micheletti, M. Marastoni, C. Fortini, A. Canella, M. Marino, R. Tomatis, S. Traniello, and R. Gavioli. 2002. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 32:144-154.
48. Wedemeyer, H., S. Gagneten, A. Davis, R. Bartenschlager, S. Feinstone, and B. Rehermann. 2001. Oral immunization with HCV-NS3-transformed Salmonella: Induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121:1158-1166.
49. Wolk, B., D. Sansonno, H. G. Krausslich, F. Dammacco, C. M. Rice, H. E. Blum, and D. Moradpour. 2000. Subcellular localization, stability, and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74:2293-2304.
50. Yasutomi, Y., S. Koenig, R. M. Woods, J. Madsen, N. M. Wassef, C. R. Alving, H. J. Klein, T. E. Nolan, L. J. Boots, J. A. Kessler, et al. 1995. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69:2228-2279.
51. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51-88.